TY - JOUR T1 - Which electronic health record system should we use? – a systematic review JF - medRxiv DO - 10.1101/2020.10.11.20210930 SP - 2020.10.11.20210930 AU - Mohammed Al Ani AU - George Garas AU - James Hollingshead AU - Drostan Cheetham AU - Thanos Athanasiou AU - Vanash Patel Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/12/2020.10.11.20210930.abstract N2 - Objectives This is the first systematic review to look at all published data on EHRs to determine which systems are advantageous.Design A systematic review was performed by searching EMBASE and Ovid MEDLINE between 1974 and November 2019.Participants All original studies that appraised EHR systems were included.Main outcome measures EHR system comparison, implementation, user satisfaction, efficiency and performance, documentation, and research and development.Results The search strategy identified 701 studies, which were filtered down to 46 relevant studies. Level of evidence ranged from 1 to 4 according to the Oxford Centre for Evidence-based Medicine. The majority of the studies were performed in the USA (n = 44). N=6 studies compared more than one EHR, and Epic followed by Cerner were the most favourable through direct comparison. N=17 studies evaluated implementation which highlighted that it was challenging, and productivity dipped in the early phase. N=5 studies reflected on user satisfaction, with women demonstrating higher satisfaction than men. Efficiency and performance issues were the driving force behind user dissatisfaction. N=26 studies addressed efficiency and performance, which improved with long-term use and familiarity. N=18 studies considered documentation and showed that EHRs had a positive impact with basic and speciality tasks. N=29 studies assessed research and development which revealed vast capabilities and positive implications.Conclusion Epic is the most studied EHR system and the most commonly used vendor on the market. There is limited comparative data between EHR vendors, so it is difficult to assess which is the most advantageous system.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published article (and its supplementary information files). ER -